Exact Therapeutics AS (OSL:EXTX) Total Operating Expense: kr84.88 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:EXTX Exact Therapeutics AS OSL:EXTX
21 GF Score
Price kr0.73
! 2 Warning Signs
View Full Analysis

What is Exact Therapeutics AS Total Operating Expense?

Exact Therapeutics AS OSL:EXTX +0.69% 21 Total Operating Expense is kr84.88 Mil as of Dec. 2025. GuruFocus rates OSL:EXTX with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Exact Therapeutics AS's Total Operating Expense for the six months ended in Dec. 2025 was kr39.02 Mil. Exact Therapeutics AS's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr84.88 Mil.

Exact Therapeutics AS Total Operating Expense Related Terms

Exact Therapeutics AS Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Exact Therapeutics AS's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Therapeutics AS Total Operating Expense Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 59.11 40.78 48.38 52.86 84.88

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.13 29.71 23.15 45.85 39.02
OSL:EXTX
21GF Score
Exact Therapeutics AS OSL:EXTX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exact Therapeutics AS Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr84.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr84.88 Mil mean?
Exact Therapeutics AS (OSL:EXTX) has a Total Operating Expense of kr84.88 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Exact Therapeutics AS and its competitors.
Is Exact Therapeutics AS's Total Operating Expense too high?
Exact Therapeutics AS's current Total Operating Expense is kr84.88 Mil. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's Total Operating Expense compare to VRTX and REGN?
Exact Therapeutics AS's Total Operating Expense of kr84.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Exact Therapeutics AS and its competitors. Exact Therapeutics AS's current Total Operating Expense is kr84.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (OSL:EXTX) has a current Total Operating Expense of kr84.88 Mil. The current Total Operating Expense is kr84.88 Mil. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Exact Therapeutics AS (OSL:EXTX), the current Total Operating Expense is kr84.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exact Therapeutics AS Business Description

Address Ostre Aker Vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score

Get the complete analysis for OSL:EXTX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.73
Price